OICR supports approximately 1,800 researchers at institutions across the province of Ontario. This page lists the recipients of OICR Investigator Awards, Associates, research fellows and the leaders of OICR’s research programs and initiatives. If you have questions or are looking for an OICR researcher not listed here, contact email@example.com.
The OICR Investigator Awards Program is designed to strengthen Ontario’s cancer research capacity by attracting and retaining outstanding researchers and clinician scientists to Ontario. The Program provides stable recruitment and retention funding for Principal Investigators and clinician scientists involved in OICR programs, strategic initiatives and other OICR supported research activities.
These appointments are designated to exceptional investigators with appointments at other academic research institutions who share scientific focus with OICR and wish to engage in innovative research collaborations around mutually advantageous activities with OICR programs, strategic initiatives and other OICR supported research activities programs.
Dr. Ailles and her team are focusing on two major research areas, intra-tumoural heterogeneity and epigenetics in clear cell renal cell carcinoma (ccRCC).
The goal of the Drug Discovery group is to optimize lead molecules and progress them to drug candidates that can translate into therapeutic benefits to cancer patients.
Dr. Aldape is a neuropathologist and laboratory scientist with research interests in brain tumours and cancer genomics in general.
Dr. Awadalla and his team focuses on next-generation genomics approaches, model-based tools and population-based approaches to study cancer.
Dr. Bartlett is developing new diagnostic approaches to improve patient diagnosis and treatment.
Dr. Bedard is Co-Principal Investigator of the Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE) study.
Dr. Bell’s lab has shown that a variety of viruses selectively replicate in and kill cancer cell lines while leaving healthy parts of the body intact.
Dr. Boutros' team uses biological big data to create new biomarkers that personalize therapy for individual patients.
Dr. Butler is Co-leader of OICR's Immuno-oncology Translational Research Initiative (ACTION).
Dr. Janet Dancey is the leader of the Canadian Cancer Clinical Trials Network (3CTN) and the Canadian Cancer Trials Group (CCTG)
Dr. Dick’s world-renowned research program centers on the theme that genetic and non-genetic determinants of tumour heterogeneity are linked through stemness.
Dr. Dirks is Co-leader of OICR's Brain Cancer Translational Research Initiative.
Dr. Feilotter focuses on the development of biomarkers to be used in the screening, diagnosis or treatment of human diseases, including cancer.
Dr. Fenster is driven by the opportunity to use technological innovations to meet the challenges of cancer diagnosis and therapy needs.
Dr. Fiume is an OICR associate researcher.
Dr. Ferretti’s expertise is in bioinformatics with experience in both large-scale software development and computational genomics.
Geoffrey T. Fong
Dr. Fong is the founder of the International Tobacco Control Policy Evaluation Project. This project's objective is to evaluate the impact of policies designed to control tobacco use.
Dr. Gallinger is Leader of OICR's Pancreatic Cancer Translational Research Initiative (PanCuRx).
The focus of Dr. Grunfeld’s research is the evaluation of access to and quality of cancer care across the cancer control continuum – from screening to end-of-life care.
Dr. Haibe-Kains is an OICR associate researcher.
Dr. Haider’s research focus is abdominal and pelvic MRI with an interest in therapeutic response assessment and quantitative imaging of cancer.
Dr. Hanna’s research focuses on three translational streams of health services research: quality of care, value of care and access to care.
The overarching goal of Dr. Hirano’s research is to devise novel anti-tumour immunotherapeutic modalities that can cure cancer.
Dr. Hope aims to identify the underlying processes that lead to the transformation of healthy cells into leukemic cells and contribute to the progression of the disease.
Dr. Jamaspishvili’s research interest and project goals are to identify and validate promising diagnostic and prognostic biomarkers for early prostate cancer.
Dr. Kornaga is an OICR associate researcher.
Dr. LeBrun’s research group studies perturbations in the regulation of gene transcription that underlie acute lymphoblastic leukemia.
Dr. Lupien’s research highlights the need to characterize and understand the role of noncoding regulatory elements as targets of genetic and epigenetic changes in oncogenesis.
Dr. McPherson is an OICR associate researcher specializing in genome technologies.
Dr. Nieman is studying the developmental impact of chemotherapy agents with a goal of improved brain development and quality of life in childhood cancer patients.
Dr. Notta is an OICR associate researcher.
Dr. Oza is Co-leader of OICR's Ovarian Cancer Translational Research Initiative.
Dr. Palma's research focuses on new imaging technologies used with radiotherapy to improve tumour targeting and to deliver higher doses of radiotherapy than previously possible.
Dr. Pearson’s lab is trying to understand the connection between adult stem cells and cancer by using the freshwater planarian as an in vivo model system.
Dr. Pond’s research interest is in statistical methodologies and analysis of cancer clinical trials, with an aim to facilitate the translation of scientific discoveries into the clinic.
Dr. Pugh is Director of the Princess Margaret-OICR Translational Genomics Laboratory and an OICR associate researcher.
The Reimand Lab develops and applies methods to interpret cancer data using pathway and network information.
The Rottapel laboratory uses functional genetic screens (both shRNA and CRISPR/Cas9) to identify novel vulnerabilities in ovarian cancer as a strategy to develop new therapeutic targets.
Dr. Schimmer is Co-leader of OICR's Acute Leukemia Translational Research Initiative.
Dr. Scholl is focusing on developing an emergent technique for molecular imaging with magnetic resonance
The Simpson lab develops algorithms and software for the analysis of high-throughput sequencing data.
Dr. Siu is Co-Principal Investigator of the Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE) study.
Dr. Stein is Head of Adaptive Oncology at OICR. His research focuses on using network and pathway-based analysis to identify common mechanisms in multiple cancer types and to devise prognostic and predictive signatures.
Dr. Taylor is Co-leader of OICR's Brain Cancer Translational Research Initiative.
Dr. Wouters’ lab has identified new signaling pathways that influence how tumours respond to environments with reduced oxygenation.
Dr. Yaffe’s research is directed toward development and improvement of imaging techniques for the earlier detection, diagnosis and treatment of cancer
Director, Genome Informatics